The phenotypic consequences of CFTR mutations

Annals of Human Genetics

Volumn 67, Issue 5, 2003, Pages 471-485

  Rowntree, Rebecca K ^a   Harris, Ann ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALLELE; AUTOSOMAL RECESSIVE DISORDER; BRONCHIECTASIS; CLINICAL FEATURE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; GALLBLADDER EPITHELIUM; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INTESTINE EPITHELIUM CELL; LUNG DISEASE; NONHUMAN; PANCREAS; PANCREATITIS; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; SWEAT GLAND;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; PHENOTYPE;

EID: 0141615605     PISSN: 00034800     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-1809.2003.00028.x     Document Type: Review

References (80)

1. Abramowicz, M. J., Dessars, B., Sevens, C., Goossens, M. & Boulandet, E. G. (2000). Fetal bowel hyperechogenicity may indicate mild atypical cystic fibrosis: a case associated with a complex CFTR allele. J Med Genet 37, E15.
2. Akabas, M. H. (2000). Cystic fibrosis transmembrane conductance regulator. Structure and function of an epithelial chloride channel [In Process Citation]. J Biol Chem 275, 3729-32.
3. Anand, R., Ogilvie, D. J., R. Butler, Riley, J. H., Finniear, R. S., Powell, S. J., Smith, J. C. & Markham, A. F. (1991). A yeast artificial chromosome contig encompassing the cystic fibrosis locus. Genomics 9, 124-30.
4. Arkwright, P. D., Laurie, S., Super, M., Pravica, V, Schwarz, M. J., Webb, A. K. & Hutchinson, I. V. (2000). TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55, 459-62.
5. Audrezet, M. P., Chen, J. M., Le Marechal, C., Ruszniewski, P., Robaszkiewicz, M., Raguenes, O., Quere, I., Scotet, V. & Ferec, C. (2002). Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. Eur J Hum Genet 10, 100-6.
6. Borgo, G., Cabrini, G., Mastella, G., Ronchetto, P, Devoto, M. & Romeo, G. (1993). Phenotypic intrafamilial heterogeneity in cystic fibrosis. Clin Genet 44, 48-9.
7. Bronsveld, I, Mekus, F., Bijman, J., Ballmann, M., de Jonge, H. R., Laabs, U, Halley, D.J., Ellemunter, H., Mastella, G., Thomas, S., Veeze, H. J. & Tummler, B. (2001). Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 108, 1705-15.
8. Buratti, E., Dork, T., Zuccato, E., Pagani, F., Romano, M. & Baralle, F. E. (2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. Embo J 20, 1774-84.
9. Cartegni, L., Chew, S. L. & Krainer, A. R..(2002). Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3, 285-98.
10. Casals, T., Ramos, M. D., Gimenez, J., Larriba, S., Nunes, V. & Estivill, X. (1997). High heterogeneity for cystic fibrosis in Spanish families: 75 mutations account for 90% of chromosomes. Hum Genet 101, 365-70.
11. Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R. & Smith, A. E. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-34.
12. Chiba-Falek, O., Kerem, E., Shoshani, T., Aviram, M., Augarten, A., Bentur, L., Tal, A., Tullis, E., Rahat, A. & Kerem, B. (1998). The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C → T mutation. Genomics 53, 276-83.
13. Choi, J. Y., Muallem, D., Kiselyov, K., Lee, M. G., Thomas, P. J. & Muallem, S. (2001). Aberrant CFTR-dependent HCO3-transport in mutations associated with cystic fibrosis. Nature 410, 94-7.
14. Chu, C. S., Trapnell, B. C., Curristin, S., Cutting, G. R. & Crystal, R. G. (1993). Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 3, 151-6.
15. Chu, C. S., Trapnell, B. C., Murtagh, J. J., Moss, J. Jr., Dalemans, W. Jallat, S., Mercenier, A., Pavirani, A., Lecocq, J. P., Cutting, G. R. & et al. (1991). Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. Embo J 10, 1355-63.
16. Clain, J., Fritsch, J., Lehmann-Che, J., Bali, M., Arous, N., Goossens, M., Edelman, A. & Fanen, P. (2001). Two mild cystic fibrosis-associated mutations result in severe cystic fibrosis when combined in cis and reveal a residue important for cystic fibrosis transmembrane conductance regulator processing and function. J Biol Chem 276, 9045-9.
17. Clancy, J. P, Bebok, Z., Ruiz, F, King, C., Jones, J., Walker, L., Greer, H., Hong, J., Wing, L., Macaluso, M., Lyrene, R., Sorscher, E. J. & Bedwell, D. M. (2001). Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163, 1683-92.
18. Cohn, J. A., Friedman, K. J., Noone, P, G., Knowles, M. R., Silverman, L. M. & Jowell, P, S. (1998). Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 339, 653-8.
19. Cuppens, H., Lin, W, Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., Jorissen, M., Droogmans, G., Reynaert, I., Goossens, M., Nilius, B. & Cassiman, J. J. (1998). Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism. as a disease mutation. J Clin Invest 101, 487-96.
20. Cystic Fibrosis Genetic Analysis Consortium 1994. Population variation of common cystic fibrosis mutations. Hum Mut 167-77
21. De Braekeleer, M., Allard, C., Leblanc, J. P, Simard, E & Aubin, G. (1997). Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation. Hum Genet 101, 208-11.
22. Dork, T., Wulbrand, U, Richter, T., Neumann, T., Wolfes, H., Wulf, B., Maass, G. & Tummler, B. (1991). Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Hum Genet 87, 441-6.
23. Drumm, M. (2001). Modifier genes and variation in cystic fibrosis. Respir Res 2, 125-128.
24. Ellsworth, R. E., Jamison, D. C., Touchman, J. W, Chissoe, S. L., Braden Maduro, V. V, Bouffard, G. G., Dietrich, N. L., Beckstrom-Sternberg, S. M., Iyer, L. M., Weintraub, L. A., Cotton, M., Courtney, L., Edwards, J., Maupin, R., Ozersky, P, Rohlfing, T., Wohldmann, P, Miner, T., Kemp, K., Kramer, J., Korf, I., Pepin, K., Antonacci-Fulton, L., Fulton, R. S., Green, D. & et al. (2000). Comparative genomic sequence analysis of the human and mouse cystic fibrosis transmembrane conductance regulator genes. Proc Natl Acad Sci U S A 97, 1172-7.
25. Estivill, X., Ortigosa, L., Perez-Frias, J., Dapena, J., Ferrer, J., Pena, L., Llevadot, R., Gimenez, J., Nunes, V & et al. (1995). Clinical characteristics of 16 cystic fibrosis patients with the missense mutation R334W a pancreatic insufficiency mutation with variable age of onset and interfamilial clinical differences. Hum Genet 95, 331-6.
26. Gabriel, S. E., Brigman, K. N., Koller, B. H., Boucher, R. C. & Stutts, M. J. (1994). Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266, 107-9.
27. Garred, P, Pressler, T., Madsen, H. O., Frederiksen, B., Svejgaard, A., Hoiby, N., Schwartz, M. & Koch, C. (1999). Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 104, 431-7.
28. Girodon, E., Cazeneuve, C., Lebargy, F, Chinet, T, Costes, B., Ghanem, N., Martin, J., Lemay, S., Scheid, R, Housset, B., Bignon, J. & Goossens, M. (1997). CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 5, 149-55.
29. Green, E. D. & Olson, M. V. (1990). Chromosomal region of the cystic fibrosis gene in yeast artificial chromosomes: a model for human genome mapping. Science 250, 94-8.
30. Haardt, M., Benharouga, M., Lechardeur, D., Kartner, N. & Lukacs, G. L. (1999). C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 274, 21873-7.
31. Hefferon, T. W, Broackes-Carter, F. C., Harris, A. & Cutting, G. R. (2002). Atypical 5′ Splice Sites Cause CFTR Exon 9 To Be Vulnerable to Skipping. Am J Hum Genet 71, 294-303.
32. Henry, M. T., Cave, S., Rendall, J., O'Connor, C. M., Morgan, K., FitzGerald, M. X. & Kalsheker, N. (2001). An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis. Eur J Hum Genet 9, 273-8.
33. Hentze, M. W. & Kulozik, A. E. (1999). A perfect message: RNA surveillance and nonsense-mediated decay. Cell 96, 307-10.
34. Higgins, C. F. (1992). ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8, 67-113.
35. Highsmith, W. E., Burch, L. H., Zhou, Z., Olsen, J. C., Boat, T. E., Spock, A., Gorvoy, J. D., Quittel, L., Friedman, K. J., Silverman, L. M. & et al. (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331, 974-80.
36. Hogenauer, C., Santa Ana, C. A., Porter, J. L., Millard, M., Gelfand, A., Rosenblatt, R. L., Prestidge, C. B. & Fordtran, J. S. (2000). Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion. Am J Hum Genet 67, 1422-7.
37. Howard, M., Frizzell, R. A. & Bedwell, D. M. (1996). Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2, 467-9.
38. Hull, J., Shackleton, S. & Harris, A. (1993). Abnormal mRNA splicing resulting from three different mutations in the CFTR gene. Hum Mol Genet 2, 689-92.
39. Hull, J. & Thomson, A. H. (1998). Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 53, 1018-21.
40. Hung, L. W, Wang, I. X., Nikaido, K., Liu, P. Q., Ames, G. F. & Kim, S. H. (1998). Crystal structure of the ATP-binding subunit of an ABC transporter [see comments]. Nature 396, 703-7.
41. Kalin, N., Claass, A., Sommer, M., Puchelle, E. & Tummler, B. (1999). DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest 103, 1379-89.
42. Kartner, N., Augustinas, O., Jensen, T. J., Naismith, A. L. & Riordan, J. R. (1992). Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1, 321-7.
43. Kerem, B., Rommens, J. M., Buchanan, J. A ., Markiewicz, D., Cox, K., Chakravarti, A., Buchwald, M. & Tsui, L.C. (1989). Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-80.
44. Kiesewetter, S., Macek, M., Davis, C. Jr, Curristin, S. M., Chu, C. S., Graham, C., Shrimpton, A. E., Cashman, S. M., Tsui, L. C., Mickle, J. & et al. (1993). A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 5, 274-8.
45. Lazaro, C., de Cid, R., Sunyer, J., Soriano, J., Gimenez, J., Alvarez, M., Casals, T., Anto, J. M. & Estivill, X. (1999). Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum Mutat 14, 510-9.
46. Mahadeva, R., Westerbeek, R. C., Perry, D. J., Lovegrove, J. U, Whitehouse, D. B., Carroll, N. R., Ross-Russell, R. I, Webb, A. K., Bilton, D. & Lomas, D. A. (1998). Alpha1-antitrypsin deficiency alleles and the Taq-I G → A allele in cystic fibrosis lung disease. Eur Respir J 11, 873-9.
47. Malats, N., Casals, T., Porta, M., Guarner, L., Estivill, X. & Real, F. X. (2001). Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group. Gut 48, 70-4.
48. Mateu, E. C. F, Ramos, M. D., Casals, T & Bertranpetit, J. (2002). Can a place of origin of the main cystic fibrosis mutations be identified? Am J Hum Genet 70, 257-64.
49. Niksic, M., Romano, M., Buratti, E., Pagani, F. & Baralle, F. E. (1999). Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR. exon 9 [In Process Citation]. Hum Mol Genet 8, 2339-49.
50. Ockenga, J., Stuhrmann, M., Ballmann, M., Teich, N., Keim, V. Dork, T. & Manns, M. P. (2000). Mutations of the cystic fibrosis gene, but not cationic trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis. Am J Gastroenterol 95, 2061-7.
51. Onay, T., Topaloglu, O., Zielenski, J., Gokgoz, N., Kayserili, H., Camcioglu, Y, Cokugras, H., Akcakaya, N., Apak, M., Tsui, L. C. & Kirdar, B. (1998). Analysis of the CFTR gene in Turkish cystic fibrosis patients: identification of three novel mutations (3172delAC, P1013L and M1028I). Hum Genet 102, 224-30.
52. Pagani, F, Buratti, E., Stuani, C., Romano, M., Zuccato, E., Niksic, M., Giglio, L., Faraguna, D. & Baralle, F. E. (2000). Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element. J Biol Chem 275, 21041-7.
53. Pier, G. B., Grout, M., Zaidi, T., Meluleni, G., Mueschenborn, S. S., Banting, G., Ratcliff, R., Evans, M. J. & Colledge, W H. (1998). Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 393, 79-82.
54. Pignatti, P. F., Bombieri, C., Benetazzo, M., Casartelli, A., Trabetti, E., Gile, L. S., Martinati, L. C., Boner, A. L. & Luisetti, M. (1996). CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 58, 889-892.
55. Popa, I., Pop, L., Popa, Z., Schwarz, M. J., Hambleton, G., Malone, G. M., Haworth, A. & Super, M. (1997). Cystic fibrosis mutations in Romania. Eur J Pediatr 156, 212-3.
56. Rave-Harel, N., Kerem, E., Nissim-Rafinia, M., Madjar, I., Goshen, R., Augarten, A., Rahat, A., Hurwitz, A., Darvasi, A. & Kerem, B. (1997). The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 60, 87-94.
57. Rich, D. P., Anderson, M. P., Gregory, R. J., Cheng, S. H., Paul, S., Jefferson, D. M., McCann, J. D., Klinger, K. W, Smith, A. E. & Welsh, M. J. (1990). Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells [see comments]. Nature 347, 358-63.
58. Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L. & et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science 1989 Sep 29;245(4925):1437]. Science 245, 1066-73.
59. Romey, M. C., Guittard, C., Carles, S., Demaille, J., Claustres, M. & Ramsay, M. (1999). First putative sequence alterations in the minimal CFTR promoter region [letter]. J Med Genet 36, 263-4.
60. Romey, M. C., Pallares-Ruiz, N., Mange, A., Mettling, C., Peytavi, R., Demaille, J. & Claustres, M. (2000). A naturally occurring sequence variation that creates a YY1 element is associated with increased cystic fibrosis transmembrane conductance regulator gene expression. J Biol Chem 275, 3561-7.
61. Rowntree, R. & Harris. A. (2002). DNA polymorphisms in potential regulatory elements of the CFTR gene alter transcription factor binding. Hum Genet 111, 66-74.
62. Rozmahel, R., Wilschanski, M., Matin, A., Plyte, S., Oliver, M., Auerbach, W, Moore, A., Forstner, J., Durie, P, Nadeau, J., Bear, C. & Tsui, L. C. (1996). Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 12, 280-7.
63. Salvatore, F., Scudiero, O. & Castaldo, G. (2002). Genotype-phenotype correlation in cystic fibrosis: The role of modifier genes. Am J Med Genet 111, 88-95.
64. Schwiebert, E. M., Benos, D. J., Egan, M. E., Stutts, M. J. & Guggino, W B. (1999). CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 79, S145-66.
65. Sharer, N., Schwarz, M., Malone, G., Howarth, A., Painter, J., Super, M. & Braganza, J. (1998). Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 339, 645-52.
66. Sheppard, D. N., Rich, D. P, Ostedgaard, L. S., Gregory, R. J., Smith, A. E. & Welsh, M. J. (1993). Mutations in CFTR associated with mild-disease-form C1- channels with altered pore properties. Nature 362, 160-4.
67. Shoshani, T., Augarten, A., Gazit, E., Bashan, N., Yahav, Y., Rivlin, Y, Tal, A., Seret, H., Yaar, L., Kerem, E. & et al. (1992). Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 50, 222-8.
68. Sobczyqska-Tomaszeska, A., Sands, D., Nowakowska, A. & Bal, J. (2002). The 1237G-A enhancer polymorphism of alpha-1 antitrypsin gene as modifier of pulmonary disease in cystic fibrosis patients. Journal of Cystic Fibrosis 1, S86-87.
69. Teng, H., Jorissen, M., Van Poppel, H., Legius, E., Cassiman, J. J. & Cuppens, H. (1997). Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum Mol Genet 6, 85-90.
70. Tsui, L. C. (1992). The spectrum of cystic fibrosis mutations. Trends Genet 8, 392-8.
71. Tzetis, M., Efthymiadou, A., Doudounakis, S. & Kanavakis, E. (2001). Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621+3A → G, 2751+2T → A, 296+1G → C, 1717-9T → C-D565G) and one nonsense mutation (E822X) in the CFTR gene. Hum Genet 109, 592-601.
72. Vankeerberghen, A., Wei, L., Jaspers, M., Cassiman, J. J., Nilius, B. & Cuppens, H. (1998a). Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator. Hum Mol Genet 7, 1761-9.
73. Vankeerberghen, A., Wei, L., Teng, H., Jaspers, M., Cassiman, J. J., Nilius, B. & Cuppens, H. (1998b). Characterization of mutations located in exon 18 of the CFTR gene. FEBS Lett 437, 1-4.
74. Wang, X., Moylan, B., Leopold, 'D. A., Kim, J., Rubenstein, R. C., Togias, A., Proud, D., Zeidin, P. L. & Cutting, G. R. (2000). Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. Jama 284, 1814-9.
75. Welsh, M., Ramsey, B. W, Accurso, F. & Cutting, G. R. (2001). Cystic Fibrosis. In The Molecular and Metabolic Basis of Inherited Disease (ed. A. B. CL Scriver, W S. Sly & D. Valle), pp. 5121-5188. McGraw-Hill, New York.
76. Zielenski, J. (2000). Genotype and phenotype in cystic fibrosis. Respiration 67, 117-33.
77. Zielenski, J., Corey, M., Rozmahel, R., Markiewicz, D., Aznarez, I., Casals, T, Larriba, S., Mercier, B., Cutting, G. R., Krebsova, A., Macek, M. Jr, Langfelder-Schwind, E., Marshall, B. C., DeCelie-Germana, J., Claustres, M., Palacio, A., Bal, J., Nowakowska, A., Ferec, C., Estivill, X., Durie, P. & Tsui, L. C. (1999). Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome l9q13 [letter]. Nat Genet 22, 128-9.
78. Zielenski, J., Patrizio, P., Corey, M., Handelin, B., Markiewicz, D., Asch, R. & Tsui, L. C. (1995). CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet 57, 958-60.
79. Zielenski J., Rozmahel, R., Bozon, D., Kerem, B., Grzelczak, Z., Riordan, J. R., Rommens, J. & Tsui, L. C. (1991). Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 10, 214-28.
80. Zielenski, J. & Tsui, L. C. (1995). Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29, 777-807.